Vermont 2025-2026 Regular Session

Vermont House Bill H0266

Introduced
2/19/25  
Refer
2/19/25  
Engrossed
3/18/25  
Refer
3/20/25  
Report Pass
5/13/25  
Report Pass
5/14/25  
Enrolled
5/29/25  
Enrolled
6/5/25  

Caption

An act relating to the 340B prescription drug pricing program

Impact

The bill mandates that hospitals participating in the 340B program report on their pricing and utilization of drugs, which adds a layer of transparency to their operations. The Green Mountain Care Board will oversee the compliance, making sure that hospitals do not inflate prices to compensate for the reduced revenue from the 340B pricing model. If hospitals argue that these pricing caps negatively affect their services, they may propose adjustments to reimbursement rates under specific conditions, allowing for some flexible responses to the new regulations.

Summary

House Bill H0266 focuses on the 340B prescription drug pricing program, aiming to regulate how hospitals charge for outpatient prescription drugs. The bill establishes new limitations whereby hospitals cannot charge a health insurer more than 120% of the average sales price for such drugs as determined by the Centers for Medicare and Medicaid Services. This initiative intends to reduce healthcare costs for patients and payers, ensuring more affordable access to necessary medications is maintained within hospital settings.

Sentiment

The sentiment around H0266 appears to be cautiously optimistic among supporters who see it as a necessary step to control rising healthcare costs. However, some stakeholders express concern over the financial pressures it may place on hospitals, particularly in rural areas where services may already be limited. The dialogue surrounding the bill reflects ongoing tensions between cost containment in healthcare and the operational realities faced by various healthcare providers.

Contention

Notable points of contention include concerns that the strict pricing limits could jeopardize some hospitals' financial sustainability, particularly those dependent on 340B revenue. Additionally, there is debate regarding the adequacy of transparency and the administrative burden of requiring hospitals to provide detailed reporting to the Green Mountain Care Board. Opponents fear that these requirements may divert essential resources away from patient care, creating logistical challenges across the board.

Companion Bills

No companion bills found.

Previously Filed As

VT H0233

An act relating to licensure and regulation of pharmacy benefit managers

VT S0098

An act relating to Green Mountain Care Board authority over prescription drug costs and the Green Mountain Care Board nomination and appointment process

VT H0766

An act relating to prior authorization and step therapy requirements, health insurance claims, and provider contracts

VT S0037

An act relating to access to legally protected health care activity and regulation of health care providers

VT H0125

An act relating to boards and commissions

VT H0414

An act relating to establishing an unused drug repository for Vermont

VT H0362

An act relating to updating statute language to reflect provider diversity

VT H0222

An act relating to reducing overdoses

VT H0165

An act relating to school food programs and universal school meals

VT H0479

An act relating to the Transportation Program and miscellaneous changes to laws related to transportation

Similar Bills

CA AB577

Health care coverage: antisteering.

CA AB1048

Health care: pain management and Schedule II drug prescriptions.

CA AB458

Importation of prescription drugs.

CA SB1361

Prescription drugs: cost sharing: pharmacy benefit managers.

NJ S3842

"Patient and Provider Protection Act."

NJ A4953

"Patient and Provider Protection Act."

IN HB1571

Pharmacists.

CA SB524

Health care coverage: patient steering.